Aurobindo Pharma Limited
NSE: AUROPHARMA BSE: AUROPHARMA
NSE
1,099.40
4.70 (0.43%)
Prev Close
1094.7
Open Price
1094
Volume
1,130,406
Today Low / High
1081.4 / 1103.5
52 WK Low / High
1010 / 1442
Range
1,044 - 1,154
BSE
1,099.55
4.70 (0.43%)
Prev Close
1094.85
Open Price
1087.15
Volume
11,856
Today Low / High
1081.75 / 1104.45
52 WK Low / High
994.35 / 1437.7
Range
1,045 - 1,155
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1099.4 (target range: 1,044 - 1,154), reflecting a change of 4.7 (0.42934%). On the BSE, it is listed at 1099.55 (target range: 1,045 - 1,155), showing a change of 4.7 (0.42928%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
28 Oct
1,094.00
0.49%
27 Oct
1,094.40
0.03%
24 Oct
1,100.00
-1.36%
23 Oct
1,120.00
-1.87%
21 Oct
1,101.10
-0.05%
20 Oct
1,106.00
-0.60%
17 Oct
1,106.00
-0.45%
16 Oct
1,113.10
-0.61%
15 Oct
1,126.00
-1.51%
14 Oct
1,136.10
-0.99%
13 Oct
1,127.70
0.81%
10 Oct
1,125.40
0.44%
09 Oct
1,097.00
2.09%
08 Oct
1,091.50
-1.90%
07 Oct
1,099.00
-0.81%
06 Oct
1,092.30
0.38%
03 Oct
1,095.00
-0.16%
01 Oct
1,086.90
-0.08%
30 Sep
1,088.00
-0.38%
Aurobindo Pharma Limited Graph
Aurobindo Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aurobindo Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,099.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,099.55 | 1,110.55 | 999.49 - 1,221.60 |
| 1,121.54 | 897.23 - 1,345.85 | ||
| 1,132.54 | 792.78 - 1,472.30 | ||
| Bearish Scenario | 1,099.55 | 1,088.55 | 979.70 - 1,197.41 |
| 1,077.56 | 862.05 - 1,293.07 | ||
| 1,066.56 | 746.59 - 1,386.53 |
Overview of Aurobindo Pharma Limited
ISIN
INE406A01037
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,409,372
Market Cap
638,533,304,326
Last Dividend
4
Official Website
IPO Date
1996-01-15
DCF Diff
-1,952.72
DCF
3,003
Financial Ratios Every Investor Needs
Stock Dividend of AUROPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-08 | August 08, 25 | 4 | 4 | 2025-08-08 | 2025-08-21 | |
| 2024-02-20 | February 20, 24 | 1.5 | 1.5 | 2024-02-20 | 2024-03-04 | |
| 2023-11-20 | November 20, 23 | 3 | 3 | 2023-11-20 | 2023-12-04 | |
| 2023-02-17 | February 17, 23 | 3 | 3 | 2023-02-17 | 2023-03-03 | |
| 2022-06-06 | June 06, 22 | 4.5 | 4.5 | 2022-06-07 | 2022-06-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 31,723.73 Cr | 13,483.86 Cr | 18,239.87 Cr | 0.5750 | 1,691.99 Cr | 0.00 Cr | 12,000.92 Cr | 3,485.88 Cr | 59.81 | 6,436.35 Cr | 0.1099 |
| 2024-03-31 | 29,001.87 Cr | 12,985.69 Cr | 16,016.18 Cr | 0.5522 | 1,522.43 Cr | 0.00 Cr | 10,450.39 Cr | 3,172.97 Cr | 54.15 | 5,764.12 Cr | 0.1094 |
| 2023-03-31 | 24,855.38 Cr | 11,641.67 Cr | 13,213.71 Cr | 0.5316 | 1,452.84 Cr | 0.00 Cr | 8,104.86 Cr | 1,927.50 Cr | 32.90 | 3,634.41 Cr | 0.0775 |
| 2022-03-31 | 23,455.49 Cr | 10,449.88 Cr | 13,005.61 Cr | 0.5545 | 1,624.62 Cr | 0.00 Cr | 7,805.88 Cr | 2,648.15 Cr | 45.20 | 4,311.42 Cr | 0.1129 |
| 2021-03-31 | 24,774.62 Cr | 10,189.77 Cr | 14,584.85 Cr | 0.5887 | 1,524.05 Cr | 0.00 Cr | 9,403.24 Cr | 5,334.84 Cr | 91.05 | 5,394.71 Cr | 0.2153 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8,235.49 Cr | 49,784.97 Cr | 17,138.04 Cr | 32,653.3200 Cr | 8,262.87 Cr | 27.38 Cr | 10,543.72 Cr | 15,455.43 Cr | 103.79 Cr | 47.57 Cr | 251.70 Cr | 14,682.3400 Cr |
| 2024-03-31 | 3,393.48 Cr | 45,071.51 Cr | 15,220.71 Cr | 29,842.8000 Cr | 6,647.63 Cr | 3,254.15 Cr | 9,808.23 Cr | 14,411.69 Cr | 270.29 Cr | 36.35 Cr | -2,202.63 Cr | 12,199.1300 Cr |
| 2023-03-31 | 4,396.29 Cr | 39,889.99 Cr | 13,038.14 Cr | 26,839.8500 Cr | 5,286.21 Cr | 889.92 Cr | 8,511.23 Cr | 12,803.60 Cr | 388.87 Cr | 0.00 Cr | -1,285.23 Cr | 11,493.7800 Cr |
| 2022-03-31 | 4,162.51 Cr | 33,921.72 Cr | 9,347.67 Cr | 24,575.9800 Cr | 3,278.96 Cr | -883.55 Cr | 7,553.85 Cr | 10,769.91 Cr | 567.85 Cr | 0.00 Cr | 223.17 Cr | 8,155.9800 Cr |
| 2021-03-31 | 5,373.47 Cr | 33,853.99 Cr | 11,925.00 Cr | 21,929.8700 Cr | 5,339.08 Cr | -34.39 Cr | 9,026.57 Cr | 9,315.51 Cr | 0.00 Cr | 0.01 Cr | 431.21 Cr | 10,665.0500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,924.6200 Cr | -1,875.8000 Cr | 119.7800 Cr | 1,956.7600 Cr | 2,178.3600 Cr | 5,563.7900 Cr | -1,967.8600 Cr | 3,485.8800 Cr | 1,603.7100 Cr | -1.0400 Cr | -735.4900 Cr |
| 2024-03-31 | 2,434.5200 Cr | -4,255.9500 Cr | 800.4200 Cr | -1,126.9800 Cr | -1,006.8400 Cr | 3,385.4300 Cr | -2,780.3300 Cr | 3,172.9700 Cr | 1,461.3100 Cr | -263.6400 Cr | -1,303.6800 Cr |
| 2023-03-31 | 2,386.7500 Cr | -3,977.7500 Cr | 1,814.4100 Cr | -333.6500 Cr | 229.7600 Cr | 4,392.2700 Cr | -2,403.8000 Cr | 2,612.5000 Cr | 2,457.6100 Cr | -439.5300 Cr | -926.7000 Cr |
| 2022-03-31 | 5,016.4800 Cr | -3,211.5600 Cr | -2,969.2700 Cr | 2,311.8400 Cr | -1,167.4000 Cr | 4,162.5100 Cr | -2,052.9100 Cr | 3,372.7400 Cr | -2,553.9300 Cr | -263.7000 Cr | 1,497.5200 Cr |
| 2021-03-31 | 3,329.0500 Cr | 598.6900 Cr | -1,364.8100 Cr | 1,455.2400 Cr | 2,583.0900 Cr | 5,329.9100 Cr | -1,873.8100 Cr | 7,343.5900 Cr | -958.9600 Cr | -234.3100 Cr | -1,593.5800 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 7,868.14 Cr | 3,239.22 Cr | 4,628.92 Cr | 0.5883 | 3,400.12 Cr | 824.75 Cr | 14.20 | 1,610.08 Cr | 0.1048 |
| 2025-03-31 | 8,382.12 Cr | 3,885.50 Cr | 4,496.62 Cr | 0.5365 | 1,570.65 Cr | 903.47 Cr | 15.56 | 1,740.91 Cr | 0.1078 |
| 2024-12-31 | 7,978.52 Cr | 3,315.41 Cr | 4,663.11 Cr | 0.5845 | 3,531.56 Cr | 845.81 Cr | 14.56 | 1,552.43 Cr | 0.1060 |
| 2024-09-30 | 7,796.07 Cr | 3,210.27 Cr | 4,585.80 Cr | 0.5882 | 3,476.32 Cr | 817.38 Cr | 14.00 | 1,577.09 Cr | 0.1048 |
| 2024-06-30 | 7,567.02 Cr | 3,072.68 Cr | 4,494.34 Cr | 0.5939 | 3,422.39 Cr | 919.22 Cr | 15.69 | 1,558.54 Cr | 0.1215 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 8,235.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -32,646.93 Cr |
| 2025-03-31 | 8,235.49 Cr | 2,632.32 Cr | 8,235.50 Cr | 5,761.49 Cr | 10,543.72 Cr | 27,162.46 Cr | 15,455.43 Cr | 49,784.97 Cr | 17,138.04 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6,868.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -30,884.96 Cr |
| 2024-09-30 | 6,839.71 Cr | 28.52 Cr | 6,868.23 Cr | 5,402.16 Cr | 10,431.86 Cr | 26,225.64 Cr | 14,924.13 Cr | 48,094.45 Cr | 17,209.49 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 6,326.36 Cr | 0.00 Cr | 0.00 Cr | 6,326.36 Cr | 0.00 Cr | 0.00 Cr | -29,850.80 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 824.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 903.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 845.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 817.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 919.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-07-20 | July 20, 15 | 2:1 |
| 2011-02-10 | February 10, 11 | 5:1 |
| 2003-10-23 | October 23, 03 | 2:1 |
| 2000-03-20 | March 20, 00 | 2:1 |
| 2000-03-06 | March 06, 00 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,687.00 | ₹4,047,671,982,389.00 | ₹2,440,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,438.50 | ₹1,709,224,809,162.00 | ₹305,872.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,576.50 | ₹1,210,448,542,500.00 | ₹133,893.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,289.40 | ₹1,073,250,238,305.00 | ₹1,828,269.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,001.25 | ₹1,007,487,347,951.00 | ₹382,044.00 |
| Mankind Pharma Limited | MANKIND | ₹2,406.50 | ₹993,303,306,185.00 | ₹271,023.00 |
| Lupin Limited | LUPIN | ₹1,918.70 | ₹876,381,321,332.00 | ₹668,996.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,432.00 | ₹649,477,080,000.00 | ₹156,752.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,099.40 | ₹638,533,304,326.00 | ₹1,130,406.00 |
| Laurus Labs Limited | LAURUSLABS | ₹959.65 | ₹518,042,964,325.00 | ₹2,714,923.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,815.10 | ₹512,222,688,416.00 | ₹339,123.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹859.70 | ₹328,892,970,258.00 | ₹338,239.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,285.90 | ₹326,238,253,926.00 | ₹63,010.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,388.40 | ₹298,396,244,362.00 | ₹56,805.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,686.00 | ₹264,021,258,954.00 | ₹36,351.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,326.00 | ₹251,362,987,122.00 | ₹89,776.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,315.50 | ₹232,887,500,000.00 | ₹17,491.00 |
| Eris Lifesciences Limited | ERIS | ₹1,628.40 | ₹221,810,151,334.00 | ₹201,101.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,296.90 | ₹210,726,538,417.00 | ₹240,869.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,740.00 | ₹201,942,452,860.00 | ₹26,058.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹905.60 | ₹178,007,565,094.00 | ₹64,648.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.00 | ₹177,893,979,648.00 | ₹220,240.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,012.00 | ₹152,935,532,352.00 | ₹30,388.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹826.50 | ₹148,034,307,555.00 | ₹240,008.00 |
| Granules India Limited | GRANULES | ₹569.95 | ₹138,309,034,684.00 | ₹457,943.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹905.95 | ₹111,143,167,221.00 | ₹89,266.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,183.00 | ₹102,633,978,906.00 | ₹5,459.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹843.00 | ₹76,403,592,867.00 | ₹103,602.00 |
| Strides Pharma Science Limited | STAR | ₹814.00 | ₹75,028,589,196.00 | ₹168,130.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹361.10 | ₹70,624,593,758.00 | ₹144,078.00 |
| FDC Limited | FDC | ₹432.05 | ₹70,342,096,792.00 | ₹151,149.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹457.20 | ₹69,998,260,918.00 | ₹100,352.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.17 | ₹51,524,532,078.00 | ₹1,087,872.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹460.00 | ₹50,124,021,900.00 | ₹1,023,719.00 |
| Innova Captab Limited | INNOVACAP | ₹809.85 | ₹46,343,608,751.00 | ₹13,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹142.23 | ₹46,156,705,461.00 | ₹7,842,918.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹481.10 | ₹43,909,997,000.00 | ₹215,251.00 |
| Suven Life Sciences Limited | SUVEN | ₹194.00 | ₹42,299,895,218.00 | ₹85,389.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,377.50 | ₹39,321,508,163.00 | ₹8,656.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹703.85 | ₹35,698,642,054.00 | ₹75,131.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹337.35 | ₹33,830,303,399.00 | ₹45,042.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹465.55 | ₹32,777,396,913.00 | ₹10,150.00 |
Key Executives
President of Biologics, Chief Executive Officer of Biologics, Vaccines and Peptid & Director
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Gender: Not Specified
Year Born: 1981
President of Chemical Research
Dr. V. K. Handa
Gender: Not Specified
Year Born: 1952
Vice Chairman & MD
Mr. Kambam Nithyananda Reddy
Gender: male
Year Born: 1958
Compliance Officer & Company Secretary
Mr. B. Adi Reddy
Gender: male
Year Born:
Senior Vice President of Global Finance & Operations
Mr. G. P. Prasad
Gender: male
Year Born:
President of Technical
Dr. S. Vijaya Kumar
Gender: Not Specified
Year Born: 1966
Chief Financial Officer
Mr. Santhanam Subramanian
Gender: male
Year Born: 1961
Head of Global Finance Operations
Dr. Sudhir Bimal Singhi
Gender: Not Specified
Year Born: 1969
Chief Quality Officer -Corporate QA
Dr. A. Rama Mohana Rao
Gender: Not Specified
Year Born: 1962
Whole-Time Director
Mr. Mettu Madan Mohan Reddy
Gender: male
Year Born: 1960
FAQs about Aurobindo Pharma Limited
Who is the CEO of the company?
The CEO is Makkapati Satakarni.
What is the current market price of the stock?
The current price is ₹1,099.40.
What is the 52-week price range?
The range is ₹1010-1442.
What is the market capitalization of the company?
The market capitalization is ₹63,853.33 crores.
What is the dividend yield?
The dividend yield is 0.36%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aurobindo Pharma Limited (ISIN: INE406A01037) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹63,853.33 crores and an average daily volume of 1,409,372 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.